• Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform
  • Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer
     

PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement (the Investment Agreement) with IntraGel Therapeutics, Ltd. (IntraGel).

The Option Agreement includes two strategic components. First, UroGen gains access to IntraGel's proprietary SRGel platform, a biodegradable, sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen. Second, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure, IntraGel’s investigational therapy for advanced head and neck cancer, following IntraGel's completion of a Phase 2 clinical study.